Dopexamine

Dopexamine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C01CA14 (WHO) ;
Identifiers
	IUPAC name 4-[2-({6-[(2-phenylethyl)amino]hexyl}amino)ethyl]benzene-1,2-diol;
CAS Number	86197-47-9 ;
PubChem CID	55483;
ChemSpider	50102 ;
UNII	398E7Z7JB5;
KEGG	D03891 ;
ChEMBL	ChEMBL77622 ;
CompTox Dashboard (EPA)	DTXSID2048666 ;
Chemical and physical data
Formula	C22H32N2O2
Molar mass	356.510 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1ccc(cc1O)CCNCCCCCCNCCc2ccccc2;
	InChI InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2 ; Key:RYBJORHCUPVNMB-UHFFFAOYSA-N ;
	(verify)

Dopexamine is a synthetic analogue of dopamine that is administered intravenously in hospitals to reduce exacerbations of heart failure and to treat heart failure following cardiac surgery. It is not used often, as more established drugs like epinephrine, dopamine, dobutamine, norepinephrine, and levosimendan work as well. It works by stimulating beta-2 adrenergic receptors and peripheral dopamine receptor D1 and dopamine receptor D2. It also inhibits the neuronal re-uptake of norepinephrine.

The most common adverse effects include fast heart beats and nausea.

It was discovered by scientists at Fisons, which licensed it to Ipsen in 1993, and Ipsen in turn licensed it to Élan in 1999. Ipsen licensed rights in North America and Japan to Circassia in 2008; the drug had never been approved in those countries. Dopexamine went off-patent in 2010.